Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J De Winter

Showing results (51-60 of 649) with videos related to

Pageof 65
Sort By:
Expert Opinion on Drug Delivery|August 24, 2016
The Absorb bioresorbable vascular scaffold for the treatment of coronary artery diseaseCarlos Collet, Robbert J de Winter, Yoshinobu Onuma, et al.
Minerva Cardioangiologica|January 31, 2018
Current evidence for the safety and efficacy of the bio-engineered dual therapy COMBO stentDeborah N Kalkman, Jaya Chandrasekhar, Robbert J de Winter, et al.
Minerva Medica|December 12, 2012
The iatrogenic pathology of percutaneous interventions in coronary arteriesX Li, R J De Winter, A C Van Der Wal
Circulation|August 29, 2012
Letter by Damman et al regarding articles, "Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)" and "American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)"Peter Damman, Robbert J de Winter, Lars Wallentin, et al.
The New England Journal of Medicine|April 12, 2013
Revascularization strategies in patients with diabetesJan J Piek, Robbert J de Winter, Jan G P Tijssen
Circulation|September 10, 2008
Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?S Matthijs Boekholdt, Robbert J de Winter, John J P Kastelein
Lancet (London, England)|June 18, 2019
ABSORB IV: will the low rate of scaffold thrombosis persist?Ruben Y G Tijssen, Robbert J de Winter, Joanna J Wykrzykowska
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|July 7, 2007
Percutaneous pulmonary valve replacement: a new development in the lifetime strategy for patients with congenital heart diseaseB J M Mulder, R J de Winter, A A M Wilde
Circulation|December 15, 1995
Value of myoglobin, troponin T, and CK-MBmass in ruling out an acute myocardial infarction in the emergency roomR J de Winter, R W Koster, A Sturk, et al.
Nederlands Tijdschrift Voor Geneeskunde|March 5, 2009
[Routine platelet aggregation inhibition not useful when using acetylsalicylic acid or clopidogrel]Miranda C A Kramer, Rienk Nieuwland, A Sturk, et al.
Pageof 65

Showing results (51-60 of 649) with videos related to

Sort By:
Pageof 65
Expert Opinion on Drug Delivery|August 24, 2016
The Absorb bioresorbable vascular scaffold for the treatment of coronary artery diseaseCarlos Collet, Robbert J de Winter, Yoshinobu Onuma, et al.
Minerva Cardioangiologica|January 31, 2018
Current evidence for the safety and efficacy of the bio-engineered dual therapy COMBO stentDeborah N Kalkman, Jaya Chandrasekhar, Robbert J de Winter, et al.
Minerva Medica|December 12, 2012
The iatrogenic pathology of percutaneous interventions in coronary arteriesX Li, R J De Winter, A C Van Der Wal
Circulation|August 29, 2012
Letter by Damman et al regarding articles, "Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)" and "American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)"Peter Damman, Robbert J de Winter, Lars Wallentin, et al.
The New England Journal of Medicine|April 12, 2013
Revascularization strategies in patients with diabetesJan J Piek, Robbert J de Winter, Jan G P Tijssen
Circulation|September 10, 2008
Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?S Matthijs Boekholdt, Robbert J de Winter, John J P Kastelein
Lancet (London, England)|June 18, 2019
ABSORB IV: will the low rate of scaffold thrombosis persist?Ruben Y G Tijssen, Robbert J de Winter, Joanna J Wykrzykowska
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|July 7, 2007
Percutaneous pulmonary valve replacement: a new development in the lifetime strategy for patients with congenital heart diseaseB J M Mulder, R J de Winter, A A M Wilde
Circulation|December 15, 1995
Value of myoglobin, troponin T, and CK-MBmass in ruling out an acute myocardial infarction in the emergency roomR J de Winter, R W Koster, A Sturk, et al.
Nederlands Tijdschrift Voor Geneeskunde|March 5, 2009
[Routine platelet aggregation inhibition not useful when using acetylsalicylic acid or clopidogrel]Miranda C A Kramer, Rienk Nieuwland, A Sturk, et al.
Pageof 65